A biomarker of myocardial fibrosis predicts long-term response to cardiac resynchronization therapy.


compared with a higher dose (0.015 g/kg/min) infusion, which reduced BP. In conclusion, further prospective randomized controlled studies are warranted to test the efficacy of non-hypotensive low-dose nesiritide such as 0.005 g/kg/min and the current dose of 0.01 g/kg/min without the bolus of 2 g/kg/min in enhancing renal function in patients with acute… (More)


2 Figures and Tables